Zappasodi, Roberta

Publications

Sort by

Co-Author Network

selected publications

Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nature communications. 2020 Academic Article GET IT
Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism. Archives of biochemistry and biophysics. 2020 Academic Article GET IT
Times cited: 2
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. Journal for immunotherapy of cancer. 2020 Conference Paper GET IT
Times cited: 4
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nature immunology. 2020 Academic Article GET IT
Times cited: 29
In vitro assays for effector T cell functions and activity of immunomodulatory antibodies. Methods in enzymology. 2019 Article GET IT
In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. The Journal of clinical investigation. 2019 Academic Article GET IT
Times cited: 6
Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Journal for immunotherapy of cancer. 2019 Conference Paper GET IT
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Journal for immunotherapy of cancer. 2019 Conference Paper GET IT
Times cited: 23
Rational design of anti-GITR-based combination immunotherapy. Nature medicine. 2019 Academic Article GET IT
Times cited: 37
Correction to: Strategies for Predicting Response to Checkpoint Inhibitors. Current hematologic malignancy reports. 2019 Article GET IT
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer cell. 2018 Academic Article GET IT
Times cited: 19
Non-conventional Inhibitory CD4⁺Foxp3^-PD-1^hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer cell. 2018 Academic Article GET IT
Times cited: 2
Strategies for Predicting Response to Checkpoint Inhibitors. Current hematologic malignancy reports. 2018 Review GET IT
Times cited: 8
Non-conventional Inhibitory CD4⁺Foxp3^-PD-1^hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer cell. 2018 Academic Article GET IT
Times cited: 48
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer cell. 2018 Review GET IT
Times cited: 137
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017 Academic Article GET IT
Times cited: 319
Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat. Hematological oncology. 2017 Letter GET IT
Times cited: 10
Interfering with Helios-induced regulatory T cell stability as a strategy for cancer immunotherapy. Translational cancer research. 2016 Editorial Article GET IT
Immunotherapy advances in uro-genital malignancies. Critical reviews in oncology/hematology. 2016 Review GET IT
Times cited: 16
Lymphoma Immunotherapy: Current Status. Frontiers in immunology. 2015 Review GET IT
Times cited: 27
Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations. Immunotherapy. 2015 Review GET IT
Times cited: 2
The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy. 2015 GET IT
Times cited: 26
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, N.Y.). 2015 Academic Article GET IT
Times cited: 3833
HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. Blood. 2015 Academic Article GET IT
Times cited: 20
Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab. Cancer research. 2014 Academic Article GET IT
Times cited: 38
Sialidase NEU4 is involved in glioblastoma stem cell survival. Cell death & disease. 2014 Academic Article GET IT
Times cited: 12
Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas. International journal of cancer. 2014 Academic Article GET IT
Times cited: 15
Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates. Cancer immunology research. 2014 Academic Article GET IT
Times cited: 16
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012. Cancer immunology, immunotherapy : CII. 2013 Article GET IT
Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. Blood. 2011 Academic Article GET IT
Times cited: 21
Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer research. 2010 Academic Article GET IT
Times cited: 91
Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma. Cancer research. 2010 Academic Article GET IT
Times cited: 30
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood. 2008 Academic Article GET IT
Times cited: 90
The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells. Haematologica. 2008 Academic Article GET IT
Times cited: 41

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Dissecting the role of CD4+ TFH-like cells as a therapeutic target and biomarker of immunotherapy activity awarded by Parker Institute for Cancer Immunotherapy Principal Investigator 2020 - 2022

more ...

less ...

Background

education and training

Ph.D., University of Milan (Italy) 2011
M.Sc., University of Bologna (Italy) 2005

Contact

full name

Roberta Zappasodi

primary email

roz4002@med.cornell.edu

VIVO Weill Cornell Medical College

Roberta Zappasodi Assistant Professor of Hematology in Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email